ClinicalTrials.gg
RecruitingNCT05477563Updated Mar 23, 2026

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

A Phase 3 interventional study of CTX001 in Beta-Thalassemia, Thalassemia and Hematologic Diseases, sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 6 sites in 4 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.

Planned enrollment
34th of 71
26 · median 25
Started
2022
with 6 others
Phase 3
12 of 91
5 open now
Primary completion
2027-06
later than 16 of 35 live
Registered
75th of 91
by date
Lead sponsor
4 of 91
Vertex Pharmaceuticals Incorporated

Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 34th largest by planned enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2022, is one of 12 in phase 3, reaches primary completion later than 16 of the 35 other live ones, and was the 75th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in beta-Thalassemia with a site in United States, or all of them as a file.
02

Study summary

This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.

03

Conditions studied

  • Beta-Thalassemia
  • Thalassemia
  • Hematologic Diseases
  • Genetic Diseases, Inborn
  • Hemoglobinopathies
  • Sickle Cell Disease
  • Sickle Cell Anemia
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants with TDT and SCD:
  • Eligible for stem cell transplant as per investigator's judgment.
  • Participants with TDT:
  • Diagnosis of TDT as defined by:
  • Documented homozygous β-thalassemia or compound heterozygous β-thalassemia including β-thalassemia/ E (HbE). Participants can be enrolled based on historical data, but a confirmation of the genotype using the study central laboratory will be required before busulfan conditioning
  • History of at least 100 milliliter (mL)/kilograms (kg)/year or 10 units/year of packed red blood cells (RBC) transfusions in the prior 2 years before signing the consent or the last rescreening for patients going through re-screening
  • Participants with SCD:
  • Diagnosis of severe SCD as defined by:
  • Documented SCD genotypes
  • History of at least two severe VOCs events per year for the previous two years prior to enrollment

Key Exclusion Criteria:

  • Participants with TDT and SCD:
  • A willing and healthy 10/10 human leukocyte antigen (HLA)-matched related donor is available per investigator's judgement
  • Prior hematopoietic stem cell transplant (HSCT)
  • and active bacterial, viral, fungal, or parasitic infection as determined by the investigator
  • Participants with TDT:
  • Participants with associated α-thalassemia and >1 alpha deletion, or alpha multiplications
  • Participants with sickle cell β-thalassemia variant
  • Participants with SCD:
  • History of untreated moyamoya syndrome or presence of moyamoya syndrome at screening

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    CTX001

    CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.

    Biological: CTX001

Interventions

  • BiologicalCTX001

    Administered by intravenous (IV) infusion following myeloablative conditioning with busulfan

    Also known as: Exagamglogene autotemcel, Exa-cel

06

What researchers measure

Primary outcomes

  1. Fetal Hemoglobin (HbF) Concentration Over Time

    Time frame: Up to 12 Months After CTX001 Infusion

  2. Total Hemoglobin (Hb) Concentration Over Time

    Time frame: Up to 12 Months After CTX001 Infusion

Secondary outcomes

  1. TDT and SCD: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Signing of Informed Consent up to 12 Months After CTX001 Infusion

  2. TDT and SCD: Proportion of Participants With Engraftment (First day of 3 Consecutive Measurements of Absolute Neutrophil Count (ANC) >=500 per Microliter [mcgL] on 3 Different Days)

    Time frame: Within 42 Days After CTX001 Infusion

  3. TDT and SCD: Time to Engraftment

    Time frame: Up to 12 Months After CTX001 Infusion

  4. TDT and SCD: Incidence of Transplant-Related Mortality (TRM) Within 100 Days After CTX001 Infusion

    Time frame: Within 100 Days After CTX001 Infusion

  5. TDT and SCD: Incidence of TRM Within 12 Months After CTX001 Infusion

    Time frame: Within 12 Months After CTX001 Infusion

  6. TDT and SCD: Incidence of All-cause Mortality

    Time frame: From Signing of Informed Consent up to 12 Months After CTX001 Infusion

  7. TDT and SCD: Relative Reduction in Annualized Volume of RBC Transfusions

    Time frame: From Day 60 up to 12 Months After CTX001 Infusion

  8. TDT and SCD: Proportion of Alleles With Intended Genetic Modification Present in Peripheral Blood Over Time

    Time frame: Up to 12 Months After CTX001 Infusion

  9. TDT and SCD: Proportion of Alleles With Intended Genetic Modification Present in CD34+ Cells of the Bone Marrow Over Time

    Time frame: Up to 12 Months After CTX001 Infusion

  10. TDT: Duration Transfusion Free in Participants

    Time frame: Up to 12 Months After CTX001 Infusion

  11. SCD: Relative Reduction in Annualized Rate of Severe Vaso-Occlusive Crises (VOCs)

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

  12. SCD: Relative Reduction in Annualized Rate of Inpatient Hospitalizations for Severe VOCs

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

  13. SCD: Relative Reduction in Annualized Duration of Hospitalization for Severe VOCs

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

  14. SCD: Relative Reduction in Haptoglobin

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

  15. SCD: Relative Reduction in Lactate dehydrogenase

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

  16. SCD: Relative Reduction in Total Bilirubin

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

  17. SCD: Relative Reduction in Indirect Bilirubin

    Time frame: From Baseline up to 12 Months After CTX001 Infusion

07

Study locations

6 of 6 sites recruiting
  • New York Presbyterian Hospital - Morgan Stanley Children's Hospital
    New York, New York 10032, United States
    Recruiting
  • Levine Children's Hospital - Hematology
    Charlotte, North Carolina 28203, United States
    Recruiting
  • TriStar Medical Group Children's Specialists - Pediatric Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
  • University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology
    Düsseldorf, Germany
    Recruiting
  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica
    Rome, Italy
    Recruiting
  • King Faisal Specialist Hospital & Research Centre - Riyadh - Hematology
    Al Mathar Ash Shamali, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Jun 2027, 58 months after the start.

Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 58 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2022
First posted
Jul 28, 2022
StartActual
Aug 2, 2022
Primary completionEst.
Jun 9, 2027
CompletionEst.
Jun 9, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05477563
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Aug 2, 2022
Primary completion
Jun 9, 2027 (estimated)
Completion
Jun 9, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
6173416777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Exagamglogene autotemcel

Start the discussion